Role of endothelin in chronic renal failure—developments in renal involvement
Department of Nephrology, Charité, Humboldt University, Berlin, Germany.
Correspondence to: C. M. Richter, Charité Campus Benjamin Franklin, Department of Nephrology, Hindenburgdamm 30, 12200 Berlin, Germany. E-mail: Richtercm{at}gmx.de
Endothelin (ET)-1 is a potent vasoconstrictor with profibrotic and proinflammatory effects. Increasing evidence suggests that ET-1 and its cognate receptors are involved in a variety of progressive renal disorders, including diabetes, hypertension and glomerulonephritis. Several laboratory studies have demonstrated elevated expression of ET-1, which colocalizes with glomerular and tubulointerstitial injury, in addition to enhanced urinary excretion. Moreover, ET-1 expression correlates with disease severity and renal function. With the availability of ET receptor antagonists, a pathogenetic role has been further corroborated in animal models, demonstrating both structural and functional improvement. Thus, antagonizing the ET system may be useful in major renal pathologies associated with glomerular and tubulointerstitial damage.